How Does Aurora Cannabis Inc (ACB) Stock Compare to its Peers?

Thursday, December 5, 2019 3:15 PM | InvestorsObserver Analysts

Aurora Cannabis Inc (ACB) is near the top in its industry group according to InvestorsObserver. ACB gets an overall rating of 31. That means it scores higher than 31 percent of stocks. Aurora Cannabis Inc gets a 59 rank in the Drug Manufacturers - Specialty & Generic industry. Drug Manufacturers - Specialty & Generic is number 144 out of 148 industries.

Click Here to get the full Stock Score Report on Aurora Cannabis Inc (ACB) Stock.

What do These Ratings Mean?

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as “good” for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 31 means the stock is more attractive than 31 percent of stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Aurora Cannabis Inc Stock Today?

Aurora Cannabis Inc (ACB) stock is trading at $2.42 as of 2:57 PM on Thursday, Dec 5, a drop of -$0.06, or -2.22% from the previous closing price of $2.48. The stock has traded between $2.42 and $2.52 so far today. Volume today is less active than usual. So far 15,221,372 shares have traded compared to average volume of 27,946,764 shares.

To see the top 5 stocks in Drug Manufacturers - Specialty & Generic click here.

Share this article:

Related Companies

Upgrade to Premium and Analyze Stocks Like a Pro

50% Off All Subscriptions
InvestorsObserver Premium
InvestorsObserver Premium
InvestorsObserver Premium
Save up to 65% with annual

InvestorsObserver Premium

$ 20.75 $ 10.38 /month
$249 $124.50 billed annually

You May Also Like

Related Articles

Where Will Celldex Therapeutics, Inc. (CLDX) Stock Go Next After It Is Up 23.13% in a Week?

Seelos Therapeutics Inc (SEEL) Stock: What Does the Chart Say?

Is Twist Bioscience Corp (TWST) Stock About to Get Hot Tuesday?

Do Traders View Takeda Pharmaceutical Co Ltd (TAK) Stock's Current Trend Positively?

Should You Buy Quotient Ltd (QTNT) Stock After it Has Fallen 2.82% in a Week?

Where Will Citius Pharmaceuticals Inc (CTXR) Stock Go Next After It Is Down 0.95% in a Week?

Related Companies